Michael McMyne has joined Valeant Pharmaceuticals International Inc.’s dermatology division as VP of sales, and Stacey Williams joined as VP of marketing. Additionally, the company announced Lainie Keller joined as VP of corporate communications.
In his new role, McMyne is responsible for the dermatology sales force. He most recently served as VP of operations for Merz North America Inc. While at Merz, McMyne launched a channel marketing team and led the integration of two key acquisitions into the company’s dermatology portfolio.
Williams has joined Valeant to oversee the marketing strategy and execution of the dermatology organization. She has diverse experience in the commercial health care segment that includes medical devices, pharmaceuticals, R&D, and manufacturing. Prior to this new role, she was senior marketing director for Merz North America, where she led strategic direction and tactical execution for a neuroscience portfolio that included biologic, pharmaceutical and medical device products.
“Michael and Stacey each have a proven track record of results, execution and strategic agility within specialty pharmaceuticals and more specifically, the specialty of dermatology,” says Bill Humphries, executive VP and company group chairman, Valeant Dermatology. “We are committed to securing the company’s future in the dermatology space, and I look forward to working with these talented leaders to realize the full potential of this key business for Valeant.”
In a newly created role, Keller is responsible for executing external corporate communications and media relations strategies for Valeant. She joined the company from Merck & Co., where she most recently served as a director of corporate media relations, overseeing corporate, financial, litigation and policy communications.
“Communicating accurately and transparently is one of our highest priorities,” says Scott Hirsch, senior VP, business strategy/communications. “Lainie’s experience in developing and leading successful, strategic communications programs on behalf of global pharma and health care companies is invaluable as we continue to transform Valeant.”